
Clairity, a breast imaging AI startup, secured $43M to advance its FDA-cleared mammogram risk prediction tool.
Key Details
- 1Clairity, founded in 2020 by radiologist Dr. Constance Lehman, raised $43 million in Series B funding.
- 2Major investors include Ace Global Equity, Santé Ventures, and the Breast Cancer Research Foundation.
- 3The AI tool predicts five-year breast cancer risk from routine mammograms.
- 4Clairity Breast received FDA de novo authorization in May 2024.
- 5The funds will support commercialization and expanding partnerships.
Why It Matters

Source
Radiology Business
Related News

AI Model Predicts Pluvicto Response in Prostate Cancer via PSMA-PET
A multimodal AI algorithm predicts response to Pluvicto therapy in mCRPC patients using PSMA-PET imaging and lab data.

DeepHealth AI Suite Expands Radiology Insights Across Modalities
DeepHealth's Radiology AI Suite enables radiologists to detect more findings and extract additional risk and disease progression information from a wide range of imaging exams.

AI Model Predicts Pluvicto Response with PSMA-PET and Labs
A multimodal AI algorithm accurately predicts which mCRPC patients will respond to Pluvicto radioligand therapy using PSMA-PET features and laboratory values.